Adjusted earnings per share, excluding certain items, climbed 21% to $2.63 in the latest quarter, comfortably surpassing analysts’ expectations
Source link
AstraZeneca shares climb after earnings beat estimates as cancer drug portfolio drives strong growth | Stock Market News
